In a significant development in the criminal proceedings arising from the alleged Coldrif cough syrup tragedy, the Madhya Pradesh High Court granted bail to two accused—a chemical supplier and a medical representative—while making it clear that the observations recorded in the order were confined solely to the consideration of their bail applications. The Court emphasized that the criminal liability of every accused must be determined individually on the basis of evidence led during the trial and that the grant of bail should not be construed as a finding on the merits of the allegations.
The case relates to the alleged deaths of several children after they consumed batches of Coldrif cough syrup that were suspected to be contaminated with diethylene glycol (DEG), a highly toxic chemical capable of causing severe kidney damage, multiple organ failure, and even death. The incident triggered a large-scale investigation into the manufacture, supply, distribution, and marketing of the medicine, resulting in criminal proceedings against several individuals associated with different stages of the pharmaceutical supply chain.
One of the applicants before the High Court was the registered proprietor of a firm engaged in supplying diethylene glycol. He argued that his role was confined to supplying chemicals in the ordinary course of business and that he had no involvement in the manufacture or formulation of the cough syrup. According to the applicant, he supplied the chemical through lawful commercial transactions and had no knowledge that it would allegedly be used in a manner that resulted in contamination. He contended that the prosecution had failed to establish any direct connection between his role as a supplier and the unfortunate deaths that followed the consumption of the medicine.
The second applicant was employed as a medical representative responsible for promoting and marketing the pharmaceutical company's products. He submitted that his duties were limited to introducing and promoting the manufacturer's medicines before doctors and medical establishments. He argued that he had no role in the manufacturing process, quality control, laboratory testing, or formulation of the cough syrup. According to him, he merely promoted sealed products supplied by the manufacturer and had no reason to suspect that the medicine was allegedly contaminated.
The State opposed both bail applications, contending that the offences under investigation were of an extremely serious nature because they involved the deaths of several children. The prosecution argued that the investigation had revealed a chain of events involving multiple individuals connected with the production, supply, and distribution of the medicine. Considering the gravity of the allegations and their impact on public health, it was submitted that the applicants should remain in judicial custody until the completion of the trial.
After considering the submissions and examining the material available at the stage of the bail proceedings, the High Court observed that the allegations against the supplier required detailed examination during the trial. The Court noted that diethylene glycol is a chemical with several lawful industrial and commercial applications and that the applicant was not alleged to be directly involved in the manufacture of the cough syrup. Whether he had any knowledge regarding the alleged misuse of the chemical or any role in the contamination of the medicine would have to be determined on the basis of evidence produced during the trial.
With regard to the medical representative, the Court observed that his role appeared to be confined to promoting and marketing the finished pharmaceutical product. At the stage of deciding the bail application, there was no material demonstrating that he had participated in the manufacturing process or exercised any control over the composition or quality of the medicine. The Court held that his exact level of knowledge and responsibility, if any, would also have to be determined after the evidence is examined during the course of the trial.
The High Court reiterated the well-established principle that criminal liability cannot be presumed merely because a person is connected with a particular stage of the supply or distribution chain. Every accused is entitled to have his individual role assessed independently. The prosecution must establish, through legally admissible evidence, the extent of each person's involvement before criminal responsibility can be fixed. At the stage of considering bail, the Court is required to assess only whether continued detention is necessary and not to determine the guilt or innocence of the accused.
While granting bail, the Court acknowledged the seriousness of the allegations and the tragic loss of young lives allegedly resulting from the consumption of contaminated medicine. However, it observed that the gravity of the offence alone cannot justify indefinite pre-trial detention when the specific role of an accused requires further examination. The Court emphasized that the principles governing the grant of bail require a balanced assessment of the allegations, the available evidence, and the individual role attributed to each accused.
The Court also clarified that the grant of bail does not amount to an acquittal or an endorsement of the defence put forward by the applicants. The observations made in the bail order are limited to the purpose of deciding whether the accused should remain in custody during the pendency of the trial. Questions relating to intention, knowledge, negligence, or criminal responsibility will be decided independently by the trial court after a full appreciation of the evidence presented by both sides.
The proceedings highlight the complex nature of criminal liability in cases involving pharmaceutical products. The manufacture and distribution of medicines involve multiple participants, including manufacturers, suppliers of raw materials, distributors, marketing personnel, and regulatory authorities. Determining the liability of each participant requires a careful examination of statutory duties, contractual obligations, quality control mechanisms, and the degree of knowledge or participation of every individual involved.
The case also underscores the importance of maintaining strict quality standards in the pharmaceutical industry. Medicines are intended to protect and improve public health, and any failure in manufacturing, testing, or quality assurance can have devastating consequences. Incidents involving allegedly contaminated medicines emphasize the need for rigorous regulatory oversight, effective quality control procedures, and strict compliance with statutory requirements governing pharmaceutical production and distribution.
By granting bail to the supplier and the medical representative, the Madhya Pradesh High Court reaffirmed that criminal proceedings must be guided by the fundamental principles of fairness and individual accountability. The Court emphasized that every accused is entitled to a fair trial and that criminal liability must ultimately be established through evidence rather than presumption. The prosecution will continue to bear the burden of proving the guilt of each accused beyond reasonable doubt, while the trial court will determine the responsibility of every individual after a comprehensive examination of the facts and evidence placed before it.
0 Comments
Thank you for your response. It will help us to improve in the future.